A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
Status:
Terminated
Trial end date:
2019-02-25
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a
placebo plus an XOI in gout participants who have moderate renal impairment and who are not
at target level of serum urate (sUA).